Open AccessAccelerating precision medicine in metastatic prostate cancer
Author(s) -
Joaquín Mateo,
Rana R. McKay,
Wassim Abida,
Rahul Aggarwal,
Joshi J. Alumkal,
Ajjai Alva,
Felix Y. Feng,
Xīn Gào,
Julie N. Graff,
Maha Hussain,
Fatima Karzai,
Bruce Montgomery,
William Oh,
Vaibhav Patel,
Dana E. Rathkopf,
Matthew B. Rettig,
Nikolaus Schultz,
Matthew R. Smith,
David B. Solit,
Cora N. Sternberg,
Eliezer Van Allen,
David J. VanderWeele,
Jake Vinson,
Howard R. Soule,
Arul M. Chinnaiyan,
Eric J. Small,
Jonathan W. Simons,
William L. Dahut,
Andrea K. Miyahira,
Himisha Beltran
Publication year - 2020
Publication title -
nature cancer
Language(s) - English
Resource type - Journals
ISSN - 2662-1347
DOI - 10.1038/s43018-020-00141-0
Subject(s) - prostate cancer , precision medicine , disease , medicine , precision oncology , intensive care medicine , personalized medicine , cancer , oncology , bioinformatics , pathology , biology
Despite advances in prostate cancer screening and treatment, available therapy options, particularly in later stages of the disease, remain limited and the treatment-resistant setting represents a serious unmet medical need. Moreover, disease heterogeneity and disparities in patient access to medical advances result in significant variability in outcomes across patients. Disease classification based on genomic sequencing is a promising approach to identify patients whose tumors exhibit actionable targets and make more informed treatment decisions. Here we discuss how we can accelerate precision oncology to inform broader genomically-driven clinical decisions for men with advanced prostate cancer, drug development and ultimately contribute to new treatment paradigms.